Document:

NUGEN
HOLDINGS, INC.

    2010
STOCK INCENTIVE PLAN

    OF

    John A.
Salatino

    

    This
Incentive Stock Option (this “Option”) is granted to the Optionee named above by
NuGen Holdings, Inc. (the “Corporation”) pursuant to the NuGen Holdings, Inc.
2010 Stock Incentive Plan (the “Plan”) as of this 9th day of February, 2010, the
date this Option was granted pursuant to the Plan. This Option provides you an
option to purchase the number of shares of the Common Stock of the Corporation
at the times and on the terms set forth below. This Option is intended to
qualify as an “Incentive Stock Option” within the meaning of § 422 of the
Internal Revenue Code of 1986, as amended (the “Code”).

     

    1. Number of Shares and
Vesting. The total number of shares of Common Stock subject to this
Option is four hundred thousand (400,000) shares. Subject to the other terms of
this Option, the shares subject to this Option shall vest and become exercisable
for a cashless purchase immediately, and you will be allowed to exercise a
maximum of 100,000 shares, during the two week period prior to the following
dates: August 31, 2010, February 28, 2011, August 31, 2011 and February 29,
2012. In the event of change of ownership of the Company or if Eric Takamura is
no longer Chairman of the Board or CEO of the Company, all shares will be
allowed to be exercised as a cashless transaction at the time of the
change.

     

    Regardless
of the foregoing schedule, this Option shall become 100% vested in the event of
a “Change in Control,” as defined in and subject to the terms of the
Plan.

     

    2. Exercise Price. The
exercise price of this Option is $0.15 per share, which is not less than the
fair market value of the Common Stock on the date of grant of this Option. The
exercise price per share shall be paid upon exercise of all or any part of each
installment which has become exercisable by you.

     

    3. Minimum Exercise. The
minimum number of shares with respect to which this Option may be exercised at
any one time is the lesser of twenty thousand (20,000) or the number of shares
as to which this Option is then exercisable.

     

    4. Assurances Upon
Exercise. The Corporation may require you, or any person to whom this
Option is transferred under paragraph 7 of this Option, as a condition of
exercising this Option: (i) to give written assurances satisfactory to the
Corporation as to such person’s knowledge and experience in financial and
business matters and/or to employ a purchaser representative reasonably
satisfactory to the Corporation who is knowledgeable and experienced in
financial and business matters, and that he or she is capable of evaluating,
alone or together with the purchaser representative, the merits and risks of
exercising this Option; and (ii) to give written assurances satisfactory to
the Corporation stating that such person is acquiring the Common Stock subject
to this Option for such person’s own account and not with any present intention
of selling or otherwise distributing the stock. The foregoing requirements, and
any assurances given pursuant to such requirements, shall be inoperative if:
(i) the issuance of the shares of Common Stock upon the exercise of this
Option has been registered under a then currently effective registration
statement under the Securities Act of 1933, as amended; or (ii) as to any
particular requirement, a determination is made by counsel for the Corporation
that such requirement need not be met in the circumstances under the then
applicable securities laws. The Corporation may, upon advice of counsel to the
Corporation, place legends on stock certificates issued upon exercise of this
Option as such counsel deems necessary or appropriate in order to comply with
applicable securities laws, including, but not limited to, legends restricting
the transfer of the stock.

     

    
      
        
        

      

      
        1

        
          

        

      

      
        
        

      

    

    5. Term. The term of
this Option commences on the date hereof and, unless sooner terminated as set
forth below or in the Plan, terminates ten (10) years from the date it was
granted. This Option may terminate prior to the expiration of its term as set
forth in the Plan.

     

    6. Notice of Exercise.
This Option may be exercised, to the extent specified above, by delivering
written notice of exercise together with the exercise price to the Secretary of
the Corporation, or to such other person as the Corporation may designate,
during regular business hours, together with such additional documents as the
Corporation may then require pursuant to the Plan. The notice must specify the
number of shares to be purchased upon exercise and a date within 15 days after
receipt of the notice by the Corporation on which the purchase is to be
completed. The exercise price must be paid in cash.

     

    7. Transferability. This
Option is not transferable, except by will or by the laws of descent and
distribution, or to a family trust owed by you, and shall be exercisable during
your life only by you. However, you may designate a third party who, in the
event of your death, would be entitled to exercise this Option, by providing a
written notice in a form satisfactory to the Secretary of the
Corporation.

     

    8. State Securities
Laws. Notwithstanding the other provisions of this Option, the
Corporation may, in its reasonable discretion, determine that the registration
or qualification of the shares of Common Stock covered by this Option is
necessary or desirable as a condition of or in connection with the exercise of
this Option. If the Corporation makes such a determination, this Option may not
be exercised in whole or in part unless and until such registration or
qualification shall have been effected or obtained free of any conditions not
acceptable to the Corporation, in its reasonable discretion. The Corporation
shall use good faith reasonable efforts to obtain or effect such registration or
qualification, but is not required to obtain or effect such registration or
qualification.

     

    9. Notices. Any notices
provided for in this Option or the Plan shall be given in writing and shall be
deemed effectively given upon receipt or, in the case of notices delivered by
the Corporation to you, five days after deposit in the United States mail,
postage prepaid, addressed to you at the address specified below or at such
other address as you hereafter designate by written notice to the Secretary of
the Corporation.

     

    10. Supremacy of the
Plan. This Option is subject to all the provisions of the Plan, a copy of
which is attached, and its provisions are hereby made a part of this Option.
This Option is further subject to all interpretations, amendments, rules and
regulations which may from time to time be promulgated and adopted pursuant to
the Plan. In the event of any conflict between the provisions of this Option and
those of the Plan, the provisions of the Plan shall control.

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

    11. Optionee
Acknowledgments. By executing this Option, you acknowledge and agree as
follows:

     

    11.1. Although
the Corporation has made a good faith attempt to qualify this Option as an
“Incentive Stock Option” within the meaning of Code § 422, the Corporation does
not warrant that this Option granted herein constitutes an “Incentive Stock
Option” within the meaning of that section, or that the transfer of stock
acquired pursuant to this Option will be treated for Federal Income Tax purposes
as specified in Code § 421.

     

    11.2. You
shall, from time to time, notify the Secretary of the Corporation in writing of
each disposition (including a sale, exchange, gift, or a transfer of legal
title) of shares of Common Stock acquired pursuant to the exercise of this
Option, within three years after acquiring those shares. Such notification shall
be in writing and shall be made within 15 days after each such disposition is
made.

     

    11.3. You
understand that if, among other things, you dispose of shares of Common Stock
granted to you pursuant to this Option within two years of the granting of this
Option to you or within one year of the transfer of such shares to you, or you
exercise this Option more than three months after termination of employment,
then such shares will not qualify for the beneficial treatment which you might
otherwise receive under Code §§ 421 and 422.

     

    11.4. You
further understand that upon exercise of this Option you may be subject to
alternative minimum tax as a result of such exercise.

     

    11.5. You and
your transferees have no rights as a shareholder with respect to any shares of
Common Stock covered by this Option until the date of the issuance of a stock
certificate for such shares.

     

    11.6. The
Corporation is not providing you with advice, warranties or representations
regarding any of the legal or tax effects to you with respect to this
grant.

     

    11.7. You
acknowledge that you are familiar with the terms of the grant made to you under
this Option and the Plan, that you have been encouraged by the Corporation to
discuss the grant and the Plan with your own legal and tax advisers, and that
you agree to be bound by the terms of the grant and the Plan.

     

    12. Withholding. You
acknowledge that federal and state income and payroll tax may apply upon
exercise of this Option. If the Corporation determines, in its sole discretion,
that withholding is required, you agree that such withholding may be
accomplished with respect to the cash compensation (if any) due to you from the
Corporation. If withholding pursuant to the foregoing sentence is insufficient
(in the sole judgment of the Corporation) to satisfy the full withholding
obligation, you agree that you will pay over to the Corporation the amount of
cash or, if acceptable to the Corporation in its sole discretion, property with
a value necessary to satisfy such remaining withholding obligation on the date
this Option is exercised or at a time thereafter specified in writing by the
Corporation.

     

    13. Entire Agreement.
This Option and the Plan constitute the entire agreement between the parties
pertaining to the subject matter contained herein and they supersede all prior
and contemporaneous agreements, representations, and understandings of the
parties. No supplement, modification, or amendment of this Option shall be
binding unless executed in writing by all of the parties. No waiver of any of
the provisions of this Option shall be deemed or shall constitute a waiver of
any other provisions, whether or not similar, nor shall any waiver constitute a
continuing waiver. No waiver shall be binding unless executed in writing by the
party making the waiver.

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

    14. Governing Law. This
Option shall be construed according to the laws of the State of Delaware and
federal law, as applicable. Any dispute relating to this Option shall be brought
and heard only in a court of competent jurisdiction in the State of
Delaware.

     

    Dated as
of the date first written above.

     

    
      	 	

              NUGEN
      HOLDINGS, INC.

              

              

              By:
      Michael Kleinman, M.D.

              

              Its:
      Compensation Committee Chairman

              

              Date:
      March 18, 2010

            

    

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

    The
undersigned:

    

    (a)           Acknowledges
receipt of the foregoing Option, agrees to its terms and understands that all
rights and liabilities with respect to this Option are set forth in this Option
and the Plan; and

     

    (b)           Acknowledges
that as of the date of grant of this Option, it sets forth the entire
understanding between the undersigned and the Corporation and its affiliates
regarding the acquisition of the Common Stock of the Corporation covered by this
Option and supersedes all prior oral and written agreements on that
subject.

    

    

    OPTIONEE:

    

    

    Name: /s/ John Salatino

    

    Address:                                                                      

                                

     

    Soc. Sec.
#:                                                                 

    

    Date:                                                                           

     

     

    
      
        
        

      

      
        5CONVERSION
AGREEMENT

    

    CONVERSION AGREEMENT dated as
of January 29, 2010 (this “Agreement”) among InovaChem, Inc., a Delaware
corporation (“InovaChem”), NuGen Mobility, Inc., a Delaware corporation
(“NuGen”), and Jardine Capital Corp. (the “Holder”).

    

    RECITALS

    

    WHEREAS, as of the date hereof, NuGen
owes the Holder an aggregate of $172,061, (the “Debt”); and

    

    WHEREAS, the Holder desires that NuGen
exchange all his Debt for 1,147,073 shares of common stock of InovaChem
simultaneous with the reverse merger (the “Reverse Merger”) of InovaChem and
NuGen, and said parties have agreed to effectuate such exchange upon the terms
and subject to the conditions set forth herein.

    

    NOW, THEREFORE, in consideration of the
premises and the mutual representations, warranties, covenants, agreements and
undertakings contained in this Agreement, and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the
parties hereby agree as follows:

    

    ARTICLE
I

    EXCHANGE

     

    Section
1.1         Exchange.  Upon
the terms and subject to the conditions set forth in this Agreement, (i)
simultaneous with the execution and delivery of this Agreement, the Holder shall
deliver to NuGen the original promissory note evidencing the Debt and (ii)
within ten days after the closing of the Reverse Merger, InovaChem shall deliver
to the Holder stock certificates representing 1,147,073 shares of common stock
of InovaChem (the “Common Stock”). It is the intention of the parties that such
exchange is a private transaction exempt from the registration requirements of
the Securities Act of 1933, as amended (the “Securities Act”). The ratio of such
exchange is based on $0.15 per share of Common Stock.

     

    Section
1.2         Restricted
Securities.    The Common Stock being issued to the
Holder hereunder are duly and validly issued, fully paid and non-assessable, and
will be free of any liens, claims or encumbrances and restrictions on transfer
other than the fact that such shares are “restricted securities” as such term is
defined under the Securities Act. Accordingly, the Common Stock received by the
Holder may only be sold or transferred pursuant to an effective registration
statement or in accordance with an exemption from registration under the
Securities Act.

     

    Section
1.3        Legend.  The
certificates evidencing the Common Stock shall contain a restrictive legend in
substantially the following form (and a stop-transfer order may be placed
against transfer of the certificates for such shares):

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE OR OTHER
JURISDICTION AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE
OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF, EXCEPT PURSUANT TO
AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY OTHER APPLICABLE
SECURITIES LAW OF ANY STATE OR OTHER JURISDICTION OR THERE IS AN OPINION OF
COUNSEL SATISFACTORY TO THE ISSUER, THAT AN EXEMPTION THEREFROM IS AVAILABLE AND
THAT SUCH DISPOSITION IS IN COMPLIANCE WITH APPLICABLE SECURITIES LAWS OF ANY
STATE OR OTHER JURISDICTION.

    

    ARTICLE
II

    REPRESENTATIONS
AND WARRANTIES OF THE HOLDER

     

    The Holder hereby represents and
warrants to NuGen and InovaChem the following:

    

    Section
2.1   Ownership of the
Debt.   The Holder is the sole owner of the Debt and has
good and marketable title to such Debt, free and clear of any title defect,
objection, security interest, pledge, encumbrance, lien, charge, claim, option,
preferential arrangement or restriction of any kind, including, but not limited
to, any restriction on the transfer or other exercise of any attributes of
ownership (collectively, “Liens”).  Neither the Holder nor his
affiliates has any interest, directly or indirectly, in any other equity in
NuGen or InovaChem or its respective affiliates, or has any other direct or
indirect interest in any tangible or intangible property of NuGen or InovaChem,
or has any direct or indirect outstanding indebtedness to or from either NuGen
or InovaChem, or related, directly or indirectly, to its respective assets,
other than as set forth on Schedule A annexed
hereto.  Upon consummation of the transactions contemplated by this
Agreement, the Holder shall have no direct or indirect interest in either NuGen
or InovaChem, other than as expressly provided for herein.

     

    Section
2.2    Authority.  The
Holder has the absolute and unrestricted right, power and authority to execute
and deliver this Agreement and all documents and instruments specified herein,
to carry out his obligations hereunder and to consummate the transactions
contemplated hereby. If the Holder is an entity, the person executing this
Agreement has been duly authorized by the Holder to execute and deliver this
Agreement on behalf of such Holder.  This Agreement has been duly
executed and delivered by the Holder and, assuming due authorization, execution
and delivery by the other parties hereto, this Agreement constitutes a legal,
valid and binding obligation of the Holder, enforceable against him in
accordance with its terms.

     

    Section
2.3     Approval of Transaction; No
Conflict.  The execution and delivery of this Agreement by the
Holder does not, and the performance of this Agreement by the Holder will not,
require any consent, approval, authorization or other action by, or filing with
or notification to, any person, entity, governmental authority or regulatory
authority, other than the possible filing by the Holder of a Form 3 and a
Schedule 13D with the Securities and Exchange Commission (the
“SEC”).  Furthermore, the execution, delivery and performance of this
Agreement by the Holder does not and will not (x) conflict with or violate any
agreement, law, rule, regulation, order, writ, judgment, injunction, decree,
determination or award to which the Holder is a party or by which any of his
assets are bound or (y) result in the creation or imposition of any Lien on the
Debt. If Holder is an entity, the execution, delivery and performance of this
Agreement by the Holder does not and will not violate or conflict with any
provision of the Articles of Incorporation or By-Laws or other organizational
documentation of the Holder

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    Section
2.4     Investment
Intent.   The Holder is an “accredited investor”, as that
term is defined in Regulation D under the Securities Act.  The Holder
acknowledges that he is able to evaluate and has such knowledge and experience
in financial or business matters that he is capable of evaluating the merits and
risks of accepting the Common Stock in exchange for the Debt. The Holder further
acknowledges that the shares of Common Stock are restricted securities, and as
such cannot be offered or sold unless they are subsequently registered under the
Securities Act and any applicable state securities laws or an exemption
therefrom is available. The Holder is receiving the Common Stock for his own
account and not with a present view towards the public sale or distribution,
other than as set forth in this Agreement. The Holder understands that the
Common Stock is being offered and sold to him in reliance upon specific
exemptions from the registration requirements of United States federal and state
securities laws and that NuGen and InovaChem are is relying upon the truth and
accuracy of, and the Holder’s compliance with, the representations, warranties,
agreements, acknowledgments and understandings of the Holder set forth herein in
order to determine the availability of such exemptions and the eligibility of
the Holder to acquire the Common Stock. The Holder and his advisors, if any,
have been furnished with all materials relating to the business, finances and
operations of both NuGen and InovaChem, including without limitation, materials
relating to the Reverse Merger and the offer and sale of the Common Stock which
have been requested by the Holder or his advisors.  The Holder and his
advisors, if any, have been afforded the opportunity to ask questions of both
NuGen and InovaChem.

     

    Section
2.5    Counsel.  The
Holder represents that he has had the opportunity to review and discuss this
Agreement with counsel of his choosing, that he knows and understands the legal
effect of this Agreement and the transactions contemplated hereby, that he
requested the exchange of his Debt to Common Stock and that he is voluntarily
executing and delivering this Agreement to NuGen and InovaChem.

     

    ARTICLE
III

    REPRESENTATIONS
AND WARRANTIES OF NUGEN AND INOVACHEM

     

    Each of NuGen and InovaChem, separately
and not severally, hereby represents and warrants to the Holder the
following:

    

    Section
3.1   Authority.  The
company is duly organized and validly existing under the laws of the State of
Delaware and has been duly authorized by all necessary and appropriate action to
enter this Agreement and consummate the transactions contemplated
herein.  The company has the absolute and unrestricted right, power
and authority to execute and deliver this Agreement and all documents and
instruments specified herein, to carry out its obligations hereunder and to
consummate the transactions contemplated hereby.  This Agreement has
been duly executed and delivered by the company and, assuming due authorization,
execution and delivery by the Holder, this Agreement constitutes a legal, valid
and binding obligation of the company, enforceable against the company in
accordance with its terms.

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    Section
3.2    Approval of Transaction; No
Conflict.  The execution and delivery of this Agreement by the
company does not, and the performance of this Agreement by the company will not,
require any consent, approval, authorization or other action by, or filing with
or notification to, any person, entity, governmental authority or regulatory
authority.  The execution, delivery and performance of this Agreement
by the company does not and will not conflict with or violate any agreement,
law, rule, regulation, order, writ, judgment, injunction, decree, determination
or award to which the company is a party.

     

    Section
3.3    Shares.  InovaChem
represents and warrants that upon issuance, the shares of Common Stock shall be
duly authorized, fully paid and non-assessable.

    

    ARTICLE
IV

    INDEMNIFICATION

     

    Section
4.1    Indemnification by the
Holder. Each of NuGen and InovaChem and their respective successors and
assigns (collectively, the “Company Parties”) shall be indemnified and held
harmless by the Holder from and against any and all damages, losses,
liabilities, taxes (including any deficiencies and penalties and interest
thereon), and costs and expenses (including, without limitation, reasonable
attorneys’ fees and disbursements) (collectively, “Damages”) resulting
from any misrepresentation, breach of warranty or nonfulfillment of any covenant
or agreement on the part of the Holder contained in this Agreement and as a
result of the transaction contemplated herein.

     

    Section
4.2   Indemnification by the
companies.  The Holder and his affiliates, consultants,
representatives and their respective successors and assigns shall be indemnified
and held harmless by each of NuGen and InovaChem from and against any and all
Damages resulting from any misrepresentation, breach of warranty or
nonfulfillment of any covenant or agreement on the part of said company
contained in this Agreement and as a result of the transaction contemplated
herein.

     

    Section
4.3   Notice.  Each
party hereto agrees to give to the other prompt notice of any claim or action by
a third party or occurrence of any event which may give rise to a claim or
action for indemnification hereunder. The failure to provide such notice shall
not release the indemnifying party from its obligations under this Article IV,
except to the extent that the indemnifying party is materially prejudiced by
such failure.

     

    ARTICLE
V

    GENERAL
PROVISIONS

     

    Section
5.1    Entire
Agreement.  This Agreement contains, and is intended as, a
complete statement of all of the terms of the arrangements and understandings
between the parties with respect to the matters provided for, and supersedes any
previous agreements and understandings between the parties with respect to those
matters.

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    Section
5.2   Governing
Law.  This Agreement shall be governed by and construed in
accordance with the laws of the State of New York applicable to agreements made
and to be performed wholly in such State, without regard to conflict of law
rules applied in such State.  EACH OF THE UNDERSIGNED HEREBY WAIVES
FOR ITSELF AND ITS PERMITTED SUCCESSORS AND ASSIGNS THE RIGHT TO TRIAL BY JURY
IN ANY ACTION OR PROCEEDING INSTITUTED IN CONNECTION WITH THIS
AGREEMENT.

     

    Section
5.3   Notices.  Any
notice required or given with respect to this Agreement shall be valid and
effective when delivered (i) by registered or U.S. post office stamped certified
mail, (ii) by a nationally recognized overnight air courier, or (iii) by hand,
in all cases to:

     

    If to
NuGen or InovaChem, to:

    

    InovaChem,
Inc.

    c/o  NuGen
Mobility, Inc.

    44645
Guilford Drive, Suite 201

    Ashburn,
VA 20147

    

    If to the
Holder, to:

    

    Jardine
Capital Corp.

    c/o
Crowell Moring

    1523 East
53rd
Street, 31st
Floor

    New York,
NY 10022

    Att: Mark
S. Lichtenstein

    

    Any party
hereto may change such address by notice given at least five (5) days in advance
to the other party in accordance with this Section.

    

    Section
5.4   Binding
Agreement.  This Agreement, including without limitation, all
the representations and warranties contained herein, shall be binding upon and
inure to the benefit of the parties hereto and their respective permitted
successors and assigns.

     

    Section
5.5    Amendment.  This
Agreement may be amended or modified only by a written instrument executed by
all the parties hereto.

     

    Section
5.6    No
Waiver.  The failure of a party at any time or times to require
performance of any provisions hereof shall in no manner be deemed to affect the
party’s right at a later time to enforce the same.  No waiver by any
party of the breach of any term contained in this Agreement, whether by conduct
or otherwise, in any one or more instances, shall be deemed to be or construed
as a further or continuing waiver of any such breach or of the breach of any
other term or provision of this Agreement.

     

    Section
5.7    References.  The
headings in this Agreement are solely for the convenience of the parties, and
are not intended to and do not limit, construe or modify any of the term and
conditions hereof.

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

    Section
5.8   Unenforceability.  If
any provision of this Agreement shall be held to be invalid or unenforceable,
such invalidity or unenforceability shall attach only to such provision and only
to the extent such provision shall be held to be invalid or unenforceable and
shall not in any way affect the validity or enforceability of the other
provisions hereof, all of which provisions are hereby declared severable, and
this Agreement shall be carried out as if such invalid or unenforceable
provision or portion thereof was not embodied herein.

     

    Section
5.9    Counterparts.  This
Agreement may be executed by facsimile and in counterparts, each of which shall
be an original, but all of which together shall constitute one and the same
agreement.

     

    Section
5.10  Further
Assurances.  The parties hereto will execute and deliver such
further instruments and documents and do such further acts and things as may be
reasonably required to carry out the intent and purposes of this
Agreement.

     

    IN WITNESS WHEREOF, the parties hereto
have executed and delivered this  Agreement on the date first written
above.

    

    
      
        	
                INOVACHEM
      INC.

              
	 
      
	
                By: 

              	
                /s/ Alan Pritzker

              
	 
      	
                Name:
      Alan Pritzker

              
	 
      	
                Title:
      Chief Financial Officer

              
	 
      
	
                NUGEN MOBILITY
      INC.

              
	 
      
	
                By: 

              	
                /s/ Eric Takamura

              
	 
      	
                Name:
      Eric Takamura

              
	 
      	
                Title:
      CEO / President

              
	 
      
	
                JARDINE CAPITAL
      CORP.

              
	 
      
	
                /s/ Mark Lichtenstein

              
	
                Jardine
      Capital Corp.

              
	
                c/o
      Crowell Moring

              
	
                1523
      East 53rd
      Street, 31st
      Floor

              
	
                New
      York, NY 10022

              
	
                Att:
      Mark S. Lichtenstein

              

      

    

    
      
         

      

      
        6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00179-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00179-of-00352.parquet"}]]